SCREENER COMPARE ANY 2 STOCKS

EXCHANGE TRADED FUND

THNR

Amplify Weight Loss Drug & Treatment ETF

$26.95 ▼ 2.05%

−$0.56 TODAY

FUND FACTS

Manager Amplify

Assets $5.39M

Expense ratio 0.59%

Inception May 21, 2024

Asset class Equity

Holdings 13

Volume 121

Avg volume 2.01K

ABOUT THIS FUND

The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.

PRICE

$26.95 ▼ DOWN 2.05% (−$0.56)

HOLDINGS

TOP 13 OF 13 · 69.60% OF THE FUND

RANK STOCK WEIGHT SHARES VALUE

01

NVO Novo Nordisk A/S 8.85% 10.47K $477.35K

02

LLY Eli Lilly and Company 8.64% 397 $466.32K

03

REGN Regeneron Pharmaceuticals, Inc. 5.92% 402 $319.26K

04

SRRK Scholar Rock Holding Corporation 5.72% 5.34K $308.65K

05

AMGN Amgen Inc. 5.56% 694 $300.1K

06

MRK Merck & Co., Inc. 5.44% 1.98K $293.29K

07

ARWR Arrowhead Pharmaceuticals, Inc. 5.05% 3.21K $272.31K

08

ABBV AbbVie Inc. 5.03% 1.06K $271.32K

09

PFE Pfizer Inc. 4.86% 9.38K $262.18K

10

HIMS Hims & Hers Health, Inc. 4.42% 8.26K $238.33K

11

VKTX Viking Therapeutics, Inc. 4.32% 7.24K $232.81K

12

AZN AstraZeneca PLC 4.07% 1.35K $219.32K

13

KLRA Kailera Therapeutics, Inc. 1.72% 5.73K $92.92K

SECTOR HOLDINGS

TECHNOLOGY IS 99.29% OF THE FUND

Healthcare 99.29%

Financial Services 0.39%

Cash & Others 0.32%

BY REGION

UNITED STATES IS 57.44% OF THE FUND

United States 57.44%

China 13.26%

Denmark 12.49%

Switzerland 5.08%

United Kingdom 4.09%

Japan 4.07%

South Korea 2.86%

— Other 0.71%